News | May 30, 2007

D.C. Declares June 3 the Official “Molecular Imaging Week”

May 31, 2007 - The week of June 3 has been declared “Molecular Imaging Week,” which coincides with SNM’s 54th Annual Meeting. In addition, the District of Columbia issued a “letter of welcome” to SNM for holding the world’s largest event for molecular imaging and nuclear medicine professionals in the city.

In a statement in the Congressional Record, Rep. James P. Moran (D-VA-8th) said, “Molecular imaging and therapy procedures provide safe, painless and cost-effective techniques to image the body and treat disease. These procedures are crucial in the early diagnosis of cancer, renal disease, cardiac disease and Alzheimer’s. Imaging procedures often identify abnormalities very early in the progress of a disease—long before many medical problems are apparent with other diagnostic tests. The techniques that are used in molecular imaging include radiotracer imaging/nuclear medicine, magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), optical imaging, the PET scan, ultrasound and others.” Moran urged his colleagues “to join me in supporting policies that will continue to keep our nation on the cutting edge of molecular imaging research.”

He says further, “Molecular imaging offers unique insights that allow a more targeted approach to evaluation and management of heart disease. It also plays a pivotal role in guiding the management of cancer: diagnosis, staging (extent and location), assessing therapeutic targets, monitoring therapy and evaluating prognosis, and is playing an increasingly significant role in conditions such as tumors, dementias (Alzheimer’s and others), movement disorders, seizures disorders and psychiatric disorders.”

In addition, “Molecular imaging delivers on the promise of ‘personalized medicine’—it can provide patient-specific information that allows tailored treatment of disease. It can show a precise (molecular) level of detail that provides new information for diagnosis. It is also key to the development of pharmaceuticals and genetic therapy. Molecular therapy can target molecules that deliver the therapeutic agent directly to the site of interest, bypassing normal tissue and avoiding the toxic side effects of many current therapies.”

The Virginia representative said that more than 4,000 individuals would be attending “the world’s largest event focused exclusively on the fields of nuclear medicine and molecular imaging.” The congressman noted that more than 20 million people require molecular/nuclear medicine procedures each year. These procedures include PET scans to diagnose and monitor treatment of cancer, diagnose neurological disease such as Alzheimer’s and stroke, cardiac stress tests, bone scans and follow-up for breast and prostate cancer patients and lung scans for blood clots.

Moran noted that SNM created the Molecular Imaging Center of Excellence, an organizational component of the society that is dedicated to all aspects of molecular imaging in the detection and management of disease.

District of Columbia Mayor Adrian M. Fenty noted that “more than 4,000 physicians, scientists, physicists and pharmacists will attend this meeting to discuss issues of concern to revolutionize modern medicine for patients through the use of molecular imaging and therapy.” He added, “SNM, the leading professional association for molecular and nuclear imaging and therapy, has 16,000 members across the world who are dedicated to improving patient care.”

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...